RSV Seasonal Vaccine Introduction and Growth Strategy
2023 guidance upgraded¹
2023 guidance¹
2023 sales guidance composition¹
Vaccines
Mid-teens % growth
Sales
8% to 10% growth
Speciality Medicines²
High single-digit % growth
Adj. operating profit
11% to 13% growth
HIV
High single-digit % growth
Adj. earnings per share
14% to 17% growth
General Medicines
Low single-digit % growth
Phasing considerations
Sales
FY sales to grow in the range 8-10%, with H2 sales growth below H1;
Q3 sales growth slightly higher than Q4, primarily due to comparators
Adj. Operating profit
FY Adj. operating profit to grow in the range 11-13%;
GSK
H2 profit growth above H1, informed by investment phasing;
Broadly similar Adj. operating profit growth anticipated across Q3 and Q4
All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q2 2023 earnings release and the 2022 Annual Report.
1. All excluding COVID-19 solutions and at CER 2. including HIV
26
26View entire presentation